Ryan A. Wilcox

University of Michigan–Ann Arbor — United States

Medicine · Health Sciences

42h-index7.8kcitations301works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(171), Chronic Lymphocytic Leukemia Research(62), T-cell and Retrovirus Studies(55), Cutaneous lymphoproliferative disorders research(53), Immune Cell Function and Interaction(52)

Publications301 total

CDK9 is a dependency in GATA-3 driven and MCL-1 independent T-cell Lymphomas
Blood Cancer Journal·2025Open Access
Gene expression profiling reveals two overarching types of ALCL with distinct targetable biology: an LLMPP study
Blood·2025
Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)
Blood·2025
Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort
Blood·2025Open Access
More than skin deep
Blood·2025Open Access
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, an Intravenous Fenretinide Phospholipid Suspension (12.5 mg/mL)
European Journal of Cancer·2025
Heartfelt intervention: A role for PVN oxytocin neurons in the prediabetic heart
The Journal of Physiology·2025Open Access
Transcriptional Analysis of Effusion-Based Lymphoma Supports a Post-Germinal Center Origin and Specific Inflammatory Signal Background
Cancers·2025Open Access
Mycosis Fungoides, Sézary Syndrome, and Cutaneous B‐Cell Lymphomas: 2025 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology·2025· 4 citedOpen Access
135 | LONG‐TERM FOLLOW UP OF THE VALOR (VENETOCLAX, LENALIDOMIDE, RITUXIMAB) IN PATIENTS W/ UNTREATED MANTLE CELL LYMPHOMA
Hematological Oncology·2025· 2 citedOpen Access
Total metabolic tumor volume for predicting cytokine release syndrome and treatment response in patients receiving bispecific antibodies for B-cell lymphoma.
Journal of Clinical Oncology·2025
A LAIR-1 targeting antibody drug conjugate for hematologic cancers.
Journal of Clinical Oncology·2025
Abstract 2081: Tissue-niche-based and cell-type-selective proteomics
Cancer Research·2025
ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome
Journal of the American Academy of Dermatology·2025· 3 cited
1220 The Phenotypic Landscape of Anaplastic Large Cell Lymphoma Supports a New Molecular Classification: An LLMPP Study
Laboratory Investigation·2025Open Access
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma
Leukemia & lymphoma/Leukemia and lymphoma·2025· 7 citedOpen Access
The GATA-3–dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas
Blood·2024· 4 citedOpen Access
Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity
npj Drug Discovery.·2024· 9 citedOpen Access
Airway ciliary microenvironment responses in mice with primary ciliary dyskinesia and central pair apparatus defects
Scientific Reports·2024Open Access
The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
Blood·2024
page 1 of 16Next →

Frequent Co-authors

Stephen M. Ansell(12), Alexandra C. Hristov(9), Koji Tamada(7), Lieping Chen(7), Youn H. Kim(7), Nathanael G. Bailey(7), Andrei I. Chapoval(6), Dallas B. Flies(6), Thomas E. Witzig(6), Megan S. Lim(6), Ahmad Halwani(5), Mark Kaminski(5), Andrew L. Feldman(5), David A. Wada(5), Ahmet Doǧan(5), Trilokraj Tejasvi(5), Gefeng Zhu(4), Andrei R. Shustov(4), Basem M. William(4), Scott E. Strome(4)